FDA Approves Tecelra Gene Therapy for Unresectable Synovial Sarcoma

The U.S. Food and Drug Administration (FDA) has granted approval for Tecelra (afamitresgene autoleucel), a groundbreaking gene therapy designed to treat adults with unresectable or metastatic synovial sarcoma. This approval represents a significant advancement in cancer treatment options for patients who have exhausted standard therapies. Synovial Sarcoma: A Rare Challenge Synovial sarcoma is a rare…

Read More

FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose

The U.S. Food and Drug Administration (FDA) has approved Zurnai, a groundbreaking nalmefene hydrochloride auto-injector designed for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients aged 12 years and older. This approval follows the agency’s earlier authorization of the first nasal spray formulation of nalmefene in May 2023. Opioid…

Read More